-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 G54eE0pKrNYmi9rPP7kHAXtdofg6QVToH2o1bEAVID294kTG3tz1ab/3soLn/y/6
 y2qfSGABLNBFaM2HlFEG/g==

<SEC-DOCUMENT>0001075880-05-000026.txt : 20050711
<SEC-HEADER>0001075880-05-000026.hdr.sgml : 20050711
<ACCEPTANCE-DATETIME>20050711081108
ACCESSION NUMBER:		0001075880-05-000026
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20051105
FILED AS OF DATE:		20050711
DATE AS OF CHANGE:		20050711

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		05946932

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc050711.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 11 July, 2005  By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
11 JULY, 2005

AUSTRALIAN PRODUCT PROMOTES HEALING IN VENOUS STASIS ULCERS

Novogen today announced the results of a Phase II clinical trial
of its wound healing compound, Glucoprime, in venous stasis ulcers.

The trial was conducted in Australia by Novogen subsidiary,
Glycotex Inc., which holds the rights to the Novogen glucan technology.

The trial involved 60 patients with chronic deep venous stasis ulcers
of the legs.

In the double-blinded trial, patients were randomised either
to a placebo arm, or to low-dose or high-dose Glucoprime arm.

The Glucoprime was formulated as a gel and applied to the
wound surface three times weekly.

Treatment was over 12 weeks and the ulcers were monitored for
size every two weeks.

Glucoprime was assessed for its effect on both the rate of wound
closure and the degree of healing.

Glucoprime promoted the rate at which wounds healed, with
Glucoprime-treated ulcers healing at a significantly faster
rate (mm2 per day) compared to placebo-treated ulcers.

The overall mean level of healing over the 12 weeks was
10 per cent (placebo), 59 per cent (0.1 per cent Glucoprime)
and 55 per cent (1.0 per cent Glucoprime),
although this outcome was confounded by the large discrepancy
in the size of the ulcers, with the two Glucoprime treatment groups
having substantially larger average ulcer sizes than the placebo group,
despite patients being randomised.

This discrepancy placed a greater challenge on the active (Glucoprime)
product, and will be addressed in future studies using wound healing
study guidelines recently published by the US Food and Drug
Administration (FDA) which advocate greater control
over ulcer size at baseline.

The trial was conducted at two sites in Australia -
Royal North Shore Hospital, Northern Metropolitan Area Health
Service (Sydney) and Heidelberg Repatriation Hospital
(Melbourne). The Principal Investigators were Dr Rod Lane
and Professor Michael Woodward.

Dr Rod Lane said the results were very encouraging,
given the chronic nature of the wounds and the fact that every
other product his team had looked at over the years had failed
to promote healing to a meaningful level.

"This is a substantial community health problem, and one
that is likely to get larger as our life expectancy increases,"
Dr Lane said.

"Glucoprime is a highly promising compound," Dr Lane added.


Professor Michael Woodward said, there was a need for better
products to promote wound healing.

"The pain, suffering and cost of leg ulcers is immense, and
these results are very encouraging," Professor Woodward said.

Executive Director of Glycotex, Inc., Professor Graham Kelly,
said the result confirmed confidence in the ability of Glucoprime
to promote wound healing.

"The fact that it has had such a positive effect in such
difficult wounds where standard care has failed suggests
that the technology has utility across a wide range of tissue
repair applications, from normal surgical wounds to injuries
to bones, cartilage and tendons," Professor Kelly said.

"Our intention in the first instance is to conduct a regulatory
study with a view to getting this product approved for marketing
for the purpose of venous stasis ulcers".

Glycotex is also planning on pursuing other applications of this
product and the technology in general across a range of wound
healing applications.

About venous stasis ulcers
Venous stasis ulcers accompany conditions such as varicose
veins where blood flow from the legs back to the heart is
impeded.  Pooling of blood in the lower limbs leads to skin
breakdown and eventual ulceration that generally requires
intensive therapy to reverse.  Effective healing of these ulcers
is very difficult and few treatments have been developed and
approved.  The development of a cost-effective and practical
treatment in the trophic (skin) ulcer area remains an
imperative for medicine.

Approximately one to two per cent of the adult population
of the Western world suffers from ulceration due to venous
insufficiency at some stage, a situation which costs the
public health system upwards of US$3 billion a year in the UK
and the US alone (Journal of Vascular Surgery, Nov 2000).

About Glucoprime
Glucoprime is a patented form of (1?3) (1?6)-beta-D-glucan,
a carbohydrate extracted from yeast cell walls and which
activates the cells within a wound that control the wound
healing process.

About Glycotex Inc
Glycotex is a US-based company specializing in the development
of products intended to promote tissue repair.
Glycotex is a subsidiary of Novogen (84.3 per cent shareholding)
and is licensed by Novogen to develop the glucan technology platform.

About Novogen
Novogen is a bio-pharmaceutical company focused on the
development of therapeutics derived from its phenolic
and glucan technology platforms.
Novogen is listed both on the Australian Stock Market (Code NRT)
and NASDAQ (Code NVGN). More information can be found at
www.novogen.com.



Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
